Literature DB >> 12759194

Keeping the lid on: a century of drug regulation and control.

Joseph Spillane1, William B McAllister.   

Abstract

Since the early 1900s, national and international drug control legislation has acted as a key site of contention between important societal actors. Physicians and pharmacists, regulators and drug companies, patients and addicts, and researchers and pharmacologists all attempted to influence formulation and interpretation of the rules that regulate access to addicting but medically useful substances. The 1970 Controlled Substances Act (CSA) consolidated and rationalized previous US domestic legislation and paid careful attention to the international aspects of the issue. Yet the CSA also incorporated long-standing fundamental disputes about who would act as gatekeepers, what criteria would be employed in regulatory decisions, and the basic goals of drug control legislation. Rather than view the CSA as a beginning or an end, it is better conceived as a major milepost in a century-long odyssey of maneuvering among interested parties for advantage in a complex regulatory environment. Instead of providing a definitive authoritative structure to which all parties must adhere, the CSA has served as a vehicle for discernment and continuous renegotiation of essential concepts such as "abuse liability".

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12759194     DOI: 10.1016/s0376-8716(03)00096-6

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  8 in total

1.  The Significance of Harm Reduction as a Social and Health Care Intervention for Injecting Drug Users: An Exploratory Study of a Needle Exchange Program in Fresno, California.

Authors:  Kris Clarke; Debra Harris; John A Zweifler; Marc Lasher; Roger B Mortimer; Susan Hughes
Journal:  Soc Work Public Health       Date:  2016-05-11

Review 2.  Nicotine self-administration research: the legacy of Steven R. Goldberg and implications for regulation, health policy, and research.

Authors:  Jack E Henningfield; Tracy T Smith; Bethea A Kleykamp; Reginald V Fant; Eric C Donny
Journal:  Psychopharmacology (Berl)       Date:  2016-10-21       Impact factor: 4.530

3.  Forbidden therapies: Santo Daime, ayahuasca, and the prohibition of entheogens in Western society.

Authors:  Marc G Blainey
Journal:  J Relig Health       Date:  2015-02

4.  Conference on abuse liability and appeal of tobacco products: conclusions and recommendations.

Authors:  Jack E Henningfield; Dorothy K Hatsukami; Mitch Zeller; Ellen Peters
Journal:  Drug Alcohol Depend       Date:  2011-03-03       Impact factor: 4.492

5.  Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: expert panel report.

Authors:  Chris-Ellyn Johanson; Robert L Balster; Jack E Henningfield; Charles R Schuster; James C Anthony; Andrea G Barthwell; John J Coleman; Richard C Dart; Charles W Gorodetzky; Charles O'Keeffe; Edward M Sellers; Frank Vocci; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2009-09-23       Impact factor: 4.492

Review 6.  Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy.

Authors:  Jack E Henningfield; Saul Shiffman; Stuart G Ferguson; Ellen R Gritz
Journal:  Pharmacol Ther       Date:  2009-04-08       Impact factor: 12.310

Review 7.  The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research.

Authors:  Jack E Henningfield; Reginald V Fant; Daniel W Wang
Journal:  Psychopharmacology (Berl)       Date:  2017-12-23       Impact factor: 4.530

8.  Interest in linkage to PrEP among people who inject drugs accessing syringe services; Miami, Florida.

Authors:  Young Jo; Tyler S Bartholomew; Susanne Doblecki-Lewis; Allan Rodriguez; David W Forrest; Jasmine Tomita-Barber; Juan Oves; Hansel E Tookes
Journal:  PLoS One       Date:  2020-04-16       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.